Form 8-K - Current report:
SEC Accession No. 0000950170-23-012985
Filing Date
2023-04-17
Accepted
2023-04-17 08:30:23
Documents
15
Period of Report
2023-04-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cadl-20230417.htm   iXBRL 8-K 87785
2 EX-99.1 cadl-ex99_1.htm EX-99 24020
3 GRAPHIC img160460863_0.jpg GRAPHIC 26606
4 GRAPHIC img212972848_0.jpg GRAPHIC 26606
  Complete submission text file 0000950170-23-012985.txt   354714

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cadl-20230417.xsd EX-101.SCH 2464
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cadl-20230417_lab.xml EX-101.LAB 14899
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cadl-20230417_pre.xml EX-101.PRE 11450
9 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20230417_htm.xml XML 4884
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 23822918
SIC: 2836 Biological Products, (No Diagnostic Substances)